Craneware Gets a Painful Growth Reset The recent woes of Edinburgh based healthcare software group Craneware have sent shockwaves through the industry.
A cyberattack in July and regulatory uncertainty surrounding the 340B drug pricing market in the US have combined to put a damper on revenue growth.
Craneware's core business remains profitable, with recurring revenue holding steady at $185 million. However, this stability comes at the expense of growth, which has flatlined for the year ending June 2027.